Evidence map›Paper›PMID 39624022›Full record

ArticleDrug testing and analysis2025

Analytical and Pharmacological Characterization of 1-(Furan-2-Carbonyl)-LSD (1F-LSD) and Comparison With 1-(Thiophene-2-Carbonyl)-LSD (1T-LSD).

Simon D Brandt, Pierce V Kavanagh, Sarah Gare, Simon P Elliott, Alexander Stratford, Adam L Halberstadt

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug testing and analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Interpol review of forensic drug chemistry, 2022-2025.Forensic science international. Synergy · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Simon D BrandtSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.ORCID https://orcid.org/0000-0001-8632-5372
Pierce V KavanaghDepartment of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for Health Sciences, St. James Hospital, Dublin 8, Ireland.ORCID https://orcid.org/0000-0002-1613-3305
Sarah GareDepartment of Chemistry, School of Physical Sciences, University of Liverpool, Liverpool, UK.ORCID https://orcid.org/0009-0000-0042-7440
Simon P ElliottElliott Forensic Consulting, Birmingham, UK.ORCID https://orcid.org/0000-0001-5219-1687
Alexander StratfordSynex Synthetics BV, Maastricht, The Netherlands.
Adam L HalberstadtDepartment of Psychiatry, University of California San Diego, La Jolla, USA.ORCID https://orcid.org/0000-0001-5096-5829

Funding

The Next Generation of Hallucinogens: A New Class of Synthetic Psychoactive DrugsR01DA041336 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HALBERSTADT, ADAM L. · 2017 to 2020
$1.4M
NIDA NIH HHS R01 DA041336
6 · The paper itself

Abstract

The classical psychedelic drug (+)-lysergic acid diethylamide (LSD) continues to attract considerable multidisciplinary interest, and over the last eight decades, many derivatives and analogs of LSD have been synthesized. One site on the ergoline scaffold of LSD that has been frequently modified is the N

Indexed as

HallucinogensLysergic Acid DiethylamideThiophenesAnimalsMaleMiceReceptor, Serotonin, 5-HT2AHallucinogensLysergic Acid DiethylamideReceptor, Serotonin, 5-HT2AThiopheneshead‐twitch responseLSDnew psychoactive substancespsychedelics

Identifiers

PMID39624022
PMCPMC12319525

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.